(AOF) – The expected drop in sales of Covid tests, associated with the low level of winter pathologies at the end of the year, should lead to a decline in the Boiron group’s turnover as well as a slight drop in operating income in 2023 compared to 2022, before other operating income and expenses. This is what the homeopathy specialist announced following its Board of Directors meeting on December 19, 2023.
Representatives of Boiron Developpement, the group’s majority shareholder, confirmed their intention, following the Simplified Public Purchase Offer (OPAS) whose timetable will be determined by the Financial Markets Authority (AMF), to implement a withdrawal of Boiron shares from the stock market “if the conditions are met”. In 2024, the group will only publish its annual and half-yearly results.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
